Rafael Holdings, Inc. (RFL)

Market Cap	68.66M +90.2%
Revenue (ttm)	1.16M +64.7%
Net Income	-33.11M
EPS	-0.77
Shares Out	52.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,747
Open	1.340
Previous Close	1.340
Day's Range	1.310 - 1.370
52-Week Range	1.120 - 3.190
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 12, 2026

About RFL

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Typ...

• Industry: Real Estate Services
• Sector: Real Estate
• Founded: 2017
• Employees: 23
• Stock Exchange: NYSE
• Ticker Symbol: RFL
• Website: https://www.rafaelholdings.com

Financial Performance

In fiscal year 2025, Rafael Holdings's revenue was $917,000, an increase of 43.96% compared to the previous year's $637,000. Losses were -$30.52 million, -11.30% less than in 2024.